**Large-scale seroepidemiology uncovers nephro-urological pathologies**

**in persons with tau autoimmunity**

**Authors:**

Andreia D. Magalhães[1†], Marc Emmenegger[1&], Elena De Cecco[1], Manfredi Carta[1‡], Karl

Frontzek[1], Andra Chincisan[1‖], Jingjing Guo[1], Simone Hornemann[1*], Adriano Aguzzi[1*]

**Affiliations:**

[1]Institute of Neuropathology, University of Zurich; CH-8091 Zurich, Switzerland

[†] Present address: Department of Neurology, Inselspital, Bern University Hospital; CH-3010

Bern, Switzerland

[&]Present address: Division of Medical Immunology, Department of Laboratory Medicine, Uni-

versity Hospital Basel; CH-4031 Basel, Switzerland

[‡]Present address: Institute of Neurology, University of Zurich; CH-8091 Zurich, Switzerland

[§] Present address: University College London, Institute of Neurology, Queen Square Brain

Bank; WC1N 1PJ London, United Kingdom

[‖] Present address: Credit Suisse; CH-8001 Zurich, Switzerland

[*]Correspondence: Simone Hornemann and Adriano Aguzzi

Institute of Neuropathology, University of Zurich; CH-8091 Zurich, Switzerland

Phone: 0041 44 255 2107

Simone.hornemann@uzh.ch and adriano.aguzzi@uzh.ch

**Running title:** Anti-tau autoantibodies

**Competing interests:**

The authors declare that they have no conflict of interest.

**Abstract:**

Intraneuronal aggregates of the microtubule-associated protein tau play a pivotal role in Alzheimer's disease and several other neurodegenerative syndromes. Anti-tau antibodies can reduce pathology in mouse models of neurodegeneration and are currently tested in humans. Here, we performed a large-scale seroepidemiological search for anti-tau IgG autoantibodies ($\alpha\tau$) on 40,497 human plasma samples. High-titer $\alpha\tau^+$ individuals were surprisingly prevalent, with hospital patients being three times more likely to be $\alpha\tau^+$ ($EC_{50} \geq 2^6$; a nominal dilution of $> 1/64$) than healthy blood donors (4.8% vs 1.6%). The prevalence increased with age over 70 years-old (RR 1.26, 95%CI 1.11-1.43, P<0.001) and was higher for women (RR 1.20, 95%CI 1.07-1.39, P=0.002). The autoantibodies bound selectively to tau, inhibited tau aggregation *in vitro*, and interfered with tau detection in plasma samples. No association was found between $\alpha\tau$ autoantibodies and neurological disorders. Instead, tau autoreactivity showed a significant association with kidney and urinary disorders (adjusted RR 1.27, 95%CI 1.10-1.45, P=0.001 and 1.40, 95%CI 1.20-1.63, P<0.001, respectively). These results suggest a previously unrecognized association between $\alpha\tau$ autoimmunity and extraneural diseases.

**Main Text:**

**INTRODUCTION**

Tau is a microtubule binding protein involved in cytoskeletal dynamics and expressed in neurons

(1, 2) and in extraneural tissues, including kindey (1-5). It plays a pivotal role in a variety of neu-

rodegenerative diseases, including Alzheimer's disease (AD) (6), progressive supranuclear palsy,

and various syndromes collectively referred to as tauopathies (7). The presence of brain neurofi-

brillary tau tangles correlates with cognitive decline (8), and plasma measurements of total and

phosphorylated tau have emerged as promising biomarkers for the detection and monitoring of AD

progression (9-12). Moreover, active and passive immunization with antibodies against a wide

range of tau epitopes can reduce pathology and functional decline in animal models of tauopathies

(13, 14) and are being tested in clinical trials of neurodegenerative diseases (15).

Natural autoantibodies are immunoglobulins generated against self-antigens in the absence of ex-

ternal antigen stimulation (16). They are a normal part of the immunoglobulin repertoire and have

physiological roles in homeostasis and surveillance, including the clearance of cellular debris, anti-

inflammatory activity, and first-line defense against pathogens (17). However, in certain situations,

natural autoantibodies can also cause pathological autoimmunity. The distinction between home-

ostatic and pathological autoantibodies is sometimes unclear and may depend on an individual's

physiological state (18). The study of natural autoantibodies can therefore inform about properties

of their targets, e.g. unrecognized protective or contributing roles in disease (19). Some natural

autoantibodies can cause neurological disorders, such as antibodies targeting the N-methyl-D-as-

partate receptor (NMDAR) in encephalitis (20) or antibodies targeting aquaporin-4 (AQP4) in

neuromyelitis optica (21). Conversely, natural antibodies against amyloid-β have been suggested

to protect and slow the progression of AD; aducanumab, a monoclonal antibody developed from

B-cells of cognitively normal older age individuals, has been studied as a treatment for AD (22).

Anti-tau autoantibodies have been detected in plasma of patients with AD (23) and Parkinson's

disease (24), but also in non-neurodegeneration controls (23). The effects, if any, of natural anti-

tau autoantibodies in modulating the risk of developing neurodegenerative diseases are unknown.

The study of individuals with anti-tau autoantibodies could clarify their potential as modifiers or

biomarkers of disease. Here, we tested 40,497 plasma samples from healthy blood donors and from

patients admitted to a university hospital in the frame of a two-sites cross-sectional study. We

found that anti-tau autoimmunity is highly specific and surprisingly frequent, with its prevalence

increasing with age. Unexpectedly, natural anti-tau autoantibodies were associated with a previ-

ously unrecognized syndrome comprising kidney and urinary disorders.

## RESULTS

### Prevalence of naturally occurring plasma anti-tau autoantibodies

We designed a cross-sectional study to investigate naturally occurring plasma IgG autoantibodies against the microtubule binding domain of tau protein (MTBD-tau) corresponding to the human truncated 4R-tau (residues 244–372 relative to 2N4R human tau). Plasma samples from 32,291 university hospital patients (age $\geq$ 18 years) and 8,206 healthy blood donors were screened by miniaturized Enzyme-Linked Immunosorbent Assay (ELISA, Figure 1A) (25-27).

We excluded 7,952 and 1,616 non-informative samples from patients and blood donors, respectively (fitting error >20% -$\log_{10}(EC_{50})$ or high background), and analyzed 24,339 patient samples and 6,590 healthy blood-donor samples (Figure 1A). A titer of -$\log_{10}(EC_{50}) \geq 1.8$, approximately corresponding to a nominal dilution of > 1/64 or an $EC_{50} \geq 2^6$, was empirically selected as a cutoff to call tau-autoreactive samples (henceforth named $\alpha\tau^+$) (25). This threshold represents the inflection point in our serial dilution assays above background and below saturation and was chosen to best balance sensitivity and specificity.1,169 hospital samples (4.80%) but only 104 healthy donor samples (1.58%) were $\alpha\tau^+$ (Figure 1A-C). Hence, anti-tau immunoreactivity was more prevalent in unselected hospital patients than in healthy individuals (P<0.001). Demographic data was available for 4,157 of the 6,590 blood donors. Median ages were 42 (IQR 29-54) and 55 years (IQR: 40-69) for healthy donors and hospital patients, respectively (P<0.001). Of the healthy blood donors, 40.9% (n=1,698) were women, whereas for the hospital group, 47.7% (n=11,609) of the patients were women (P<0.001). Multivariate log-binomial regression (28, 29) adjusted for age and sex showed that hospital patients had a 2.3x higher risk than healthy donors to be $\alpha\tau^+$ (aRR 2.30, 95%CI 1.83-2.92, P<0.001, Figure 1D).

The replicability of the microELISA screen was found to be high ($R^2$=0.84, P<0.001, Figure 1E).

There was no cross-reactivity to two other proteins implicated in neurodegeneration, amyloid-ß

pyroglutamate and the cellular prion protein ($PrP^C$) (27). Of 12,297 patient samples, 604 samples

were positive against MTBD-tau and 5 against amyloid-ß pyroglutamate but none was cross-reac-

tive against both targets (P=1, $\chi^2$ test) (Figure 1F), Moreover, of 13,099 patient samples, 694 were

reactive against MTBD-tau and 15 against $PrP^C$, but again none was cross-reactive against both

targets (P=0.734, $\chi^2$ test) (Figure 1G).

**Specificity and biological activity of $\alpha\tau^+$ samples**

To investigate their specificity, we purified anti-tau autoantibodies by MTBD-tau affinity chroma-

tography from four individual $\alpha\tau^+$ patients (P1-P4) and from a pool of six $\alpha\tau^+$ sample (patient_IDs:

J909190817, J802220975, J909190382, J90806029, J908060881 and J805040458). Purified anti-

MTBD-tau autoantibody samples had $EC_{50}$ values of 0.042-14.45 µg/ml whereas the mouse anti-

MTBD-tau antibody RD4 (30) had $EC_{50}$=0.002 µg/ml (Figure 2A). In a soluble-competition im-

munoassay (Figure 2B), purified $\alpha\tau^+$ autoantibodies showed a concentration-dependent binding to

recombinant MTBD-tau purified by cation exchange and size exclusion chromatography and to a

pool of 8 synthetic MTBD-tau peptides but not to albumin or an unrelated synthetic peptide (Figure

2C). To probe for polyreactivity, purified $\alpha\tau^+$ autoantibodies were tested against several structur-

ally unrelated autoantigens and bacterial proteins, including MTBD-tau, albumin, cardiolipin,

DNA, insulin, and lipopolysaccharides (LPS). Anti-tau autoantibodies were reactive against

MTBD-tau but not against any of the other antigens or uncoated plates (Figure 2D).

In immunofluorescent stainings, purified $\alpha\tau$ autoantibodies co-localized to cytoplasmic EGFP-

0N4RTau in SH-SY5Y cells and showed similar binding patterns to an anti-tau mouse monoclonal

antibody H7, but not to non-transfected cells (Figure 2E). On western blots, purified $\alpha\tau$ autoanti-

bodies detected tau-specific bands in cell lysates of SH-SY5Y cells overexpressing tau$^{P301L/S320F}$,

but not in parental (wt) SH-SY5Y cells (Figure 2F and Supplemental Figure 1). Hence, the immu-

noreactivity of $\alpha\tau^+$ samples was highly specific for tau. All IgG subclasses and both $\kappa$ and $\lambda$ light

chains were present in $\alpha\tau^+$ patients' samples (Figure 2G and H). Epitope mapping and light-chain

typing revealed a polytypic response in at least 8 out of the 13 $\alpha\tau^+$ samples (Figure 2H and I).

To investigate whether purified $\alpha\tau^+$ autoantibodies interfere with the aggregation of MTBD-tau,

samples from patients P7 and P8 were tested in an *in vitro* tau aggregation assay (31). MTBD-tau

aggregation was induced by heparin and shaking and monitored using Thioflavin T (ThT; Figure

3A). The presence of $\alpha\tau^+$ autoantibodies reduced the plateau of the ThT fluorescence signal in the

kinetic trace by about half, whereas antibodies purified by protein G affinity chromatography from

an $\alpha\tau^-$ patient had no effect (Figure 3A). Hence, $\alpha\tau^+$ autoantibodies were able to specifically bind

to and inhibit MTBD-tau aggregation *in vitro*.

Plasma tau is a promising biomarker of progression for several neurological diseases (9-12, 32).

We examined the effects of $\alpha\tau$ autoantibodies onto the performance of plasma tau immunoassays

(Figure 3B). Purified $\alpha\tau$ autoantibodies from 5 patients (P2-P6) were added to tau$^{441}$-spiked

plasma. After incubation, the amount of free tau$^{441}$ was analyzed by ELISA using commercial anti-

tau antibodies for capture (BT2, epitope on human tau$^{441}$: residues 194-198) and detection

(ab64193, epitope on non-phosphorylated and phosphorylated human tau$^{441}$ surrounding residue

262) (33). Purified $\alpha\tau$ autoantibodies P4-P6 induced a concentration-dependent impairment of de-

tection of tau$^{441}$ hampering the detection of plasma-spiked tau$^{441}$ by approximately tenfold at

higher anti-MTBD-tau autoantibody concentration (Figure 3C and D). In contrast, P2-P3 did not

show any significant impairment of the detection of plasma-spiked tau[441]. This variability of inter-

ference is explained by the binding epitopes on tau[441]. P4-P6 occupy tau residues 244 to 282 in-

cluding the binding epitope of ab64193, whereas P2-P3 occupy residues 273 to 327 which are

outside the epitope of ab64193 (Figure 3C and D and Supplemental Figure 2). Hence, the presence

of $\alpha\tau^+$ autoantibodies can interfere with the detection of plasma tau in immunoassays depending

on the combination of epitopes of the patient samples and of commercial antibodies used in im-

munoassays.

**Demographic characteristics of tau-immunoreactive patients**

The age of $\alpha\tau^+$ patients (median: 58 years; IQR: 43-71) was significantly higher than that of $\alpha\tau^-$

(median: 55; IQR: 40-68; P < 0.001, Figure 4A). Univariate logistic regression analyses of health

records for the 24,339 hospital patients showed that the prevalence of $\alpha\tau$ immunoreactivity in-

creased with age, from 3.9% in patients aged <29 years to 7.6% in patients aged >90 years

(P<0.001, Figure 4B). A log-binomial regression model (28, 29) estimated that the RR for the

presence of anti-MTBD-tau autoantibodies was highest for patients aged 70-99 years (RR 1.26,

95% CI 1.11-1.43, P<0.001, Figure 4C) and for women (RR 1.20, 95% CI 1.07-1.39, P=0.002,

Figure 4C). Due to the association of anti-MTBD-tau autoantibodies with increased age and female

sex, all further RRs were calculated using a multivariate log-binomial regression model adjusted

for age and sex. To identify potential correlations between $\alpha\tau^+$ and specific diseases, we analyzed

the admission to clinical departments. The highest RRs for $\alpha\tau^+$ were found for angiology (aRR

1.84, 95% CI 1.21-2.63, P=0.002) and nephrology (aRR 1.50, 95% CI 1.16-1.89, P=0.001, Figure

4D-E), whereas no significant difference was found between the percentage of $\alpha\tau^+$ and $\alpha\tau^-$ patients

from the department of neurology (Figure 4D).

**Neurological disorders and anti-tau autoimmunity**

We next mined pseudonymized clinical diagnoses from the clinical records of the USZ pertaining to the diagnoses of 23,375 patients as represented by ICD-10 codes (Figure 5A). Given the involvement of tau in neurodegenerative diseases (6), we focused on evaluating the association between anti-MTBD-tau autoantibodies and neurological diseases, which we categorized in 23 main groups of disorders. No associations between $\alpha\tau^+$ and neurological diseases were identified (Figure 5A). We further performed a targeted screen using plasma samples from 47 patients with AD and 68 similarly aged non-AD patients selected from our plasma biobank (median age of AD patients 78 years, IQR 70,5-86, and median age of control patients 81 years, IQR 71-85, Supplemental Table 1). Samples were tested for anti-MTBD-tau IgG autoantibodies, as in the primary screen, and additionally for anti-MTBD-tau IgA autoantibodies and anti-full-length-tau (tau441) IgG and IgA autoantibodies. No significant difference in reactivity was observed between the plasma samples from AD patients and non-AD controls in this small convenience cohort (Figure 5B), which is in line with the previous finding that the presence of autoantibodies targeting MTBD-tau is unrelated to AD or other neurological disorders.

**Systemic disorders and anti-tau autoimmunity**

We next assessed possible associations between tau autoimmunity and extraneural diseases, which we binned into 27 main groups of disorders (Figure 6A). After adjustment for multiple comparisons, $\alpha\tau$ immunoreactivity showed significant associations with vascular disorders (aRR 1.51, 95% CI 1.28-1.77, P<0.001), nutritional disorders (aRR 1.31, 95% CI 1.14-1.50, P<0.001), anemia (aRR 1.49, 95% CI 1.21-1.82, P<0.001), kidney disorders (aRR 1.27, 95% CI 1.10-1.45, P=0.001)

and urinary disorders (aRR 1.40, 95%CI 1.20-1.63, P<0.001) (Figure 6A), whereas no association

was observed among patients with autoimmune disorders (Supplemental Figure 3). There was no

difference in the coincidence of all comorbidities between $\alpha\tau^+$ samples (5, 0.46%) and $\alpha\tau^-$ samples

(69, 0.33%) (P=0.633).

To address potential biases arising from grouping and selecting major categories, we explored the

association between $\alpha\tau^+$ and individual ICD-10 codes. Across 276 individual ICD-10 codes and

after correction for multiple comparisons, eight exhibited significant associations with $\alpha\tau^+$ (Figures

6B and C). These included "E61–deficiency of other nutrient elements" (aRR 2.22, 95% CI 1.54-

3.06, P<0.001), "I74–arterial embolism and thrombosis*"* (aRR 2.09, 95% CI 1.40-2.94, P<0.001),

"N30–cystitis" (aRR 1.84, 95% CI 1.32-2.47, P<0.001), "I70–atherosclerosis*"* (aRR 1.57, 95% CI

1.29-1.89, P<0.001), "D50–iron deficiency anemia*"* (aRR 1.50, 95% CI 1.21-1.82, P<0.001),

"N39–other urinary disorders" (aRR 1.40, 95% CI 1.19-1.64, P<0.001), "B96–other bacterial

agents as the cause of diseases*"* (aRR 1.40, 95% CI 1.17-1.66, P<0.001) and "N18–chronic kidney

disease*"* (aRR 1.38, 95% CI 1.18-1.60, P<0.001; Figure 6C). Conversely, we found no significant

negative association between tau autoreactivity and any ICD-10 codes that could suggest a de-

creased risk for a specific disease in $\alpha\tau^+$ patients (Figure 6C). To verify relevant associations, we

used Bayesian logistic regression using logit-transformed $EC_{50}$ values (-logit[$EC_{50}$]) as a continu-

ous outcome. All the previously referred eight ICD-10 codes showed positive associations with -

logit[$EC_{50}$] (Figure 6D).

To validate these conditions as significant associations with plasma MTBD-tau IgG autoantibod-

ies, we examined the association between $\alpha\tau^+$ and 106 commonly requested laboratory parameters

(Supplemental Table 2) using data available for 24,177 patients, independently of any ICD-10

classifiers. After correction for multiple comparisons, the laboratory markers "Leukocytes, urine",

"Potassium" and "Urea" were positively associated with tau autoimmunity (Figure 6E). The asso-

ciation with increasing levels of urea and potassium suggests a link to kidney failure, whereas

leukocytes in urine are a feature of urinary tract infections. These findings support the hypothesis

that anti-tau autoimmunity correlates with such disorders. Accordingly, the prevalence of chronic

kidney disease was 12.4% in $\alpha\tau^-$ and 17.7% in $\alpha\tau^+$ patients, whereas that of other urinary disorders

was 10.3% in $\alpha\tau^-$ and 15.1% in $\alpha\tau^+$ patients (Figure 6F).

**DISCUSSION**

This study was designed to discover novel associations between autoreactivity to tau and human

diseases. This approach of "reverse immunopathology" is hypothesis-free: it does not pose con-

straints on the type of diseases that might result from anti-tau immunity. While the approach is

generally applicable to any autoantigen, its predictive power relies on the analysis of large patient

collectives, which in turn requires the development of high-throughput methods at reasonable cost.

We therefore miniaturized antibody detection to 3 µl/sample in 1,536-well microplates, allowing

to run 40,000 assays/24 hrs with minimal hands-on time. We performed >300,000 immunoassays

on >40,000 plasma samples for $\alpha\tau$ autoreactivity. Each sample was measured at eight dilution

points, enabling precise and unambiguous titer determinations (25-27).

Plasma $\alpha\tau$ IgG were more prevalent in women and increased with age, reaching 7.6% in the cohort

of 90-99-year-olds. The specificity of $\alpha\tau^+$ plasma to MTBD-tau was high and was confirmed by

multiple assays including epitope mapping. The age- and sex-adjusted $\alpha\tau^+$ rate in hospital patients

was three-fold higher than in healthy blood donors and considerably exceeded the previously re-

ported seroprevalences of autoantibodies targeting other intracellular neuronal targets (0.4% and

2%) (34), suggesting a potential correlation with disease states (34).

However, we did not find any association between $\alpha\tau^+$ and any neurological conditions including

neurodegenerative diseases using both ICD-10 classification as well as a convenience AD and

non-AD cohort of plasma samples, corroborating with reports of similar levels of plasma tau au-

toantibodies in AD patients and non-demented controls (35). Instead, we uncovered a robust, spe-

cific association between $\alpha\tau^+$ positivity and kidney and urinary disorders. This was independently

validated by associations with higher prevalence of positive samples from the department of Neph-

rology, grouped kidney and urinary diseases, individual kidney and urinary diagnosis codes and

related clinical laboratory biomarkers, such as high serum urea and potassium and high urine leu-

kocytes.

Seroepidemiological studies cannot establish causality: $\alpha\tau$ seropositivity could be a cause or a

consequence of the clinical syndromes associated with it (36). Therefore, due to its design, this

study cannot conclude on the homeostatic or pathological role of the anti-tau IgG autoantibodies

identified in the plasma of patients and healthy blood donors. However, tau is expressed in ex-

traneural tissues, including kidney podocytes and urinary bladder (2-5), and its ablation causes

glomerular pathologies (37).

These findings raise the possibility that plasma $\alpha\tau$ autoantibodies might drive kidney and/or uro-

logical pathologies. Alternatively, they could reflect a physiological autoimmunity with low affin-

ity autoantibodies playing a role in immune surveillance and the clearance of debris. Another pos-

sibility is that an underlying pathological process causing renal/bladder tissue injury and inflam-

mation, may lead to the extracellular release of intracellular proteins, including tau. Damage to

tubular epithelial cells or glomerular structures may expose intracellular tau to the immune system,

potentially breaking tolerance and triggering the emergence of natural or low-affinity IgG autoan-

tibodies against tau. Renal dysfunction may also impair clearance of circulating antibodies or im-

mune complexes, allowing even normally subclinical reactivity to become detectable. If the asso-

ciation between tau autoantibodies and kidney/urinary disease is epiphenomenal rather than causal

these autoantibodies may represent useful biomarkers of these diseases. Therefore, it will be im-

portant to monitor renal and urinary function in the current clinical trials of tau immunotherapy

(38-40).

Recent studies have explored the use of tau measurements in plasma as biomarkers for AD diag-

nosis and for monitoring its progression (9-12, 32, 41-45) However, we found that anti-MTBD-

tau autoantibodies could hinder tau detection in plasma by binding to epitopes recognized by com-

mercial biomarker immunoassays. The extent of this interference likely depends on both the

epitopes present and the design of the diagnostic assay, varying with the specific tau analytes tar-

geted in the assay and the particular epitopes recognized by the patients' autoantibodies. This

aligns with prior research indicating that both plasma anti-tau autoantibodies and administered

anti-tau antibodies can influence the dynamics of tau levels in plasma (46). Additionally, a recent

community cohort study using an immunoassay for AD screening revealed associations between

plasma tau levels and numerous comorbidities, with chronic kidney disease showing one of the

strongest associations (47). These results imply that the presence of anti-tau autoantibodies in

plasma might impact the effectiveness of plasma tau as an AD biomarker. This consideration may

become crucial as plasma tau levels move toward routine clinical use in AD diagnosis.

**Limitations**

Our large-scale assessment of plasma tau autoimmunity has certain limitations. Firstly, most sam-

ples analyzed in our study came from a university hospital cohort, implying a bias towards com-

plex pathologies and polymorbidities. To account for this, we included a vast collection of samples

from healthy blood donors. Secondly, our study is confined to two sites within a single region with

approximately 1,500,000 inhabitants whose ethnic composition was not thoroughly examined. Ad-

ditionally, a direct comparison of the prevalence of plasma anti-tau antibodies in these two cohorts

may potentially suffer from variations in materials, collection methods (e.g. addition of heparin

that may cause aggregation of MTBD-tau), and handling processes at the two different sites.

Thirdly, our study is restricted to the analysis of specific disease groups, the absence of an inde-

pendent replication cohort and the lack of a longitudinal disease design. These constraints restrict

our ability to verify our findings, assess temporal dynamics and the origin of these autoantibodies,

and explore potential causal relationships, including reverse causality, such as the presence of tau

antibodies in patient cohorts with renal diseases. Fourthly, the detected anti-tau antibodies may

crossreact with proteins expressed in the kidney or urinary tract, which could contribute to the

observed association with kidney and urinary disorders. To explore this possibility, we performed

an *in silico* analysis using BLASTP (https://blast.ncbi.nlm.nih.gov/) and compared the MTBD-tau

to proteins in the human kidney and urinary proteome (UniProt/Swiss-Prot). This analysis identi-

fied residues 368–461 of nicotinamide phosphoribosyltransferase (NAMPT) as a region with no-

tably high sequence identity to MTBD-tau (~28%; Supplementary Figure 4). NAMPT is a meta-

bolic enzyme with broad tissue distribution but relatively low expression in the kidney and urinary

tract (48). Nevertheless, such sequence-based analysis is limited detecting linear or conformational

epitopes that might mediate cross-reactivity. Furthermore, the statistical analysis of the association

of MTBD-tau-autoreactivity and different disorders was based on ICD-10, a medical classification

focused on reimbursement and cause-of-death statistics (49). We therefore performed additional

statistical analyses using laboratory parameters, which have provided further support for the asso-

ciation of tau autoimmunity and systemic disorders. Finally, we used bacterially expressed MTBD-

tau as target, thereby excluding full-length, other isoforms (such as big tau, a high molecular

weight (~110 kDa) tau isoform that includes exon 4a in the MAPT transcript (50)) or post-trans-

lationally modified tau epitopes, like the phosphorylated forms p-tau181 (51) and p-tau217 (52),

that are increasingly used as biomarkers for AD diagnosis. As a result, our methodology may miss

plasma anti-tau autoantibodies associated with AD pathology and could underestimate the preva-

lence of total anti-tau autoantibodies. Furthermore, this approach may introduce a bias towards

detecting autoantibodies targeting total peripheral tau which is more abundant in plasma (53).

Therefore, larger studies with well-powered AD patient cohorts may be needed to more robustly

assess the prevalence of autoantibodies selectively targeting brain-derived tau and to clarify their

potential association with neurodegeneration.

**Conclusions**

Our study identified a high seroprevalence of anti-MTBD-tau IgG autoantibodies in both plasma

samples from university hospital patients and healthy blood donors. Tau autoimmunity is associ-

ated with female sex, older age and previously unrecognized extraneural diseases. These findings

point to unrecognized roles for tau and anti-tau autoantibodies in extraneural pathologies.

**MATERIALS AND METHODS**

**METHODS**

**Sex as a biological variable**

Plasma samples from patients of both sexes were examined in this study.

**Study design**

From December 2017 until February 2020, residual heparin plasma samples were obtained from

the Department of Clinical Chemistry, University Hospital of Zurich, USZ, Switzerland. Samples

were collected during routine clinical care from patients admitted either as inpatients or outpatients

(age $\geq$ 18 years) and were only included if basic demographic data was available, and an informed

consent for research had been provided. From March until July 2020, EDTA plasma samples from

blood donors were obtained from the Blood Donation Center of Zurich, Switzerland, according to

standard criteria of blood donation. Exclusion criteria were as reported (25). Plasma samples were

biobanked locally and tested in an automated indirect microELISA ((25-27) and below) for natural

IgG autoantibodies against the MTBD-tau. Demographic and clinical data for the hospital cohort

was obtained from clinical records of the USZ with follow-up until December 2021, while detailed

clinical data for the blood donor cohort were not available for this study. ICD-10 codes (54) were

used for clinical data assessment. AD patients were selected using ICD-10 code F00 or G30. Non-

neurodegeneration controls were defined by the lack of any Fxx or Gxx ICD-10 codes.

**Automated microELISA screen**

Plasma samples were tested for natural anti-MTBD-tau IgG autoantibodies in a microELISA

screen (25-27). Briefly, high-binding 1,536-well microplates (Perkin Elmer, SpectraPlate 1536

HB) were coated with 1 µg/mL of recombinant MTBD-tau (37 °C, 60 min). Plates were washed

3x with phosphate-buffered saline 0.1% Tween®20 (PBST) using a Biotek El406 washer-dis-

penser and blocked with 5% milk (Migros)-PBST for 90 min. Plasma samples were diluted 1:20

in 1% milk-PBST and dispensed into the MTBD-tau-coated plates using ultrasound dispensing

with an ECHO 555 Liquid Handler (Labcyte/Beckman Coulter). Each sample was tested at eight

serial two-fold dilutions (1:50 to 1:6,000) using different volumes to a final volume of 3 µL/well.

Human IgG-depleted serum (MyBioSource) was used as negative and anti-tau RD4 (4-repeat iso-

form) mouse monoclonal antibody (30) (05-804 clone 1E1/A6 Merck Millipore) as positive con-

trol. Plates were incubated for 120 min at room temperature (RT) and washed 5x with PBST.

Secondary antibody peroxidase AffiniPure® goat anti-mouse IgG H+L (115-035-003, Jackson

ImmunoResearch) 1:2,000 diluted in 1% milk-PBST for the RD4 positive control, peroxidase Af-

finiPure® goat anti-human IgG Fcγ-specific (109-035-098, Jackson ImmunoResearch) 1:4,000

diluted in 1% milk-PBST for the plasma samples and the IgG-depleted serum negative control

were dispensed into the plates using a Biotek MultifloFX dispenser. Plates were incubated for 60

min, at RT and washed 3x with PBST. 3,3',5,5'-Tetramethylbenzidine (TMB) Chromogen Solution

for ELISA (Invitrogen) was added as colorimetric horseradish peroxidase (HRP) substrate for 3

min at RT. Finally, 0.5 M $H_2SO_4$ was added to stop the reaction. Plates were briefly centrifuged

after each dispensing step except after dispensing of TMB. Plates were read at Optical Density =

450 nm ($OD_{450nm}$) in a plate reader (Perkin Elmer, Envision).

For the replicability assessment, 308 samples were tested in duplicates, running the replicates on

the same day but using different 1536-well assay (destination) plates, different plate coordinates

for each replicate, and calculating the -$\log_{10}(EC_{50})$ of each replicate independently.

Non-specific cross-reactivity was assessed by testing plasma samples against MTBD-tau and am-

yloid-ß pyroglutamate (13,099 hospital patients' plasma samples) and the cellular prion protein

(PrP$^C$) (12,297 hospital patients' samples) using a similar protocol as described above.

**Production and purification of recombinant tau**

The gene encoding the human truncated 4R-tau corresponding to MTBD-tau was cloned into a

pRSET-A plasmid (Invitrogen) and expressed in *E.coli* BL21(DE3) cells. Cultures were grown in

Luria Broth (LB, Invitrogen) at 37 °C, induced with 1 mM isopropyl-β-D-thiogalactoside (IPTG)

at an OD$_{600}$ of 0.8 and grown for additional 6 h at 37 °C before harvesting by centrifugation

(6,000$g$, 10 min, 4 °C). Pellets were suspended and sonicated (30 min, 4 °C) in 20 mM piperazine-

N,N-bis(2-ethanesulfonic) acid (PIPES), pH 6.5, 1 mM ethylenediaminetetraacetic acid (EDTA)

and 50 mM 2-mercaptoethanol and. After addition of NaCl to a final concentration of 500 mM ,

samples were boiled (95 °C, 20 min) and centrifuged (9,000$g$, 30 min, 4 °C). Ammonium sulfate

was slowly added to a final concentration of 55% m/v and the suspension was stirred (1 h, room

temperature (RT)). Samples were centrifuged (15,000$g$, 10 min, 4 °C), pellets were resuspended

in 20 mM 4-(2-hydroxyethyl)piperazine-1-ethanesulfonic acid (HEPES), pH 7.0, 2 mM dithio-

threitol (DTT), passed through a 0.45 µm Acrodisc® filter (Sigma) and loaded onto Sepharose SP

Fast Flow resin (Cytiva). Tau was eluted using a linear salt gradient from 0 to 1 M NaCl in 20 mM

HEPES, pH 7.0, 2 mM DTT. Fractions containing tau were concentrated using Amicon® Ultra-

15 centrifugal filter unit (10-kDa MWCO, Merck) and dialyzed overnight at 4°C against phos-

phate-buffered saline (PBS, pH 7.4, Kantonsapotheke Zurich), 1mM DTT. Pooled samples were

passed through a HiLoad 26/60 Superdex75 (GE Healthcare) column. Protein samples were ana-

lyzed by SDS-PAGE and samples containing tau were concentrated using an Amicon® Ultra-15

centrifugal filter unit (10-kDa MWCO). Samples were assessed by SDS-PAGE and electrospray

ionization-mass spectrometry. Pure MTBD-tau samples were stored until further use at -80°C. The

concentration of tau was determined using a bicinchoninic acid assay (Pierce BCA Protein Assay

Kit, Thermo Fisher).

For the purification of full-length tau, a similar protocol was used with the following changes. The

gene encoding the longest 4R isoform of human full-length tau protein, tau[441], (tau/pET29b,

Addgene #16316, gift from Peter Klein (55)) was cloned into a pRSET-A plasmid (Invitrogen).

For protein expression, E.*coli* BL21(DE3)pLysS cells were transformed with the pRSET-A plas-

mid encoding tau[441]. Cells were grown in Overnight Express™ Instant TB media (Novagen) for 6

h at 37 °C and then for 12 h at 25 °C. Fractions containing full-length tau were concentrated using

Amicon® Ultra-15 centrifugal filter unit (30-kDa MWCO, Merck).

**402    Purification of anti-tau autoantibodies from patient samples**

Heparin plasma (3- 20 mL) was diluted 1:3.3 in PBS, and centrifuged at 6,000 $g$ for 10 min at 4

°C. The supernatant was loaded onto 3 mL of epoxy-MTBD-tau (prepared by overnight incubation

of MTBD-tau and epoxy resin in 0.1 M $NaH_2PO_4$–NaOH, 1 M NaCl, pH 9.2) by repetitive loading

of the plasma sample overnight at 4 °C. After washing with 50 mL of PBS, MTBD-tau autoanti-

bodies were eluted 4x with 5 mL 0.1 M glycine–HCl, pH 2.5, and immediately neutralized to pH

7.0 with 1 M Tris-HCl, pH 8.5. Anti-MTBD-tau antibody-containing fractions were identified by

indirect ELISA and concentrated stepwise using Amicon® Ultra-15, Ultra-4, and Ultra-0.5 mL

centrifugal filter units (50-kDa MWCO) up to a volume of 1 mL

**412    Competitive ELISA**

For the competitive sandwich ELISAs for the detection of tau, high-binding 384-well plates (Perkin Elmer, SpectraPlate 384 HB) were coated with 4 µg/mL BT2 tau monoclonal antibody (#MN1010, Thermo Fisher) in PBS. Recombinant human tau[441] (rPeptide) was diluted to a final concentration of 0.015 ng/mL and incubated with purified anti-tau autoantibodies four-fold serially diluted (1:1.66 to 1:106.6) in 1:2 plasma under rotation at 500 rpm for 120 min at 37°C. Samples were transferred to BT2-coated plates and incubated for 45 min at RT. After washing 4x with PBST, plates were incubated with ab64193 (polyclonal IgG antibody; Abcam, 0.125 µg/mL) for 45 min at RT. Plates were washed 4x with PBST and incubated with peroxidase AffiniPure® goat anti-Rabbit IgG (H+L, 111-035-045, Jackson ImmunoResearch, at a 1:2,000 dilution for 60 min at RT. Plates were washed 4x with PBST and 1-Step™ Ultra TMB-ELISA solution (Thermo Fisher) was added for 7 min at RT. After addition of 0.5 M $H_2SO_4$, plates were read at $OD_{450}$ nm in a plate reader (Perkin Elmer, Envision).

For the competitive ELISAs of MTBD-tau autoantibodies, high-binding 384-well plates were coated with 20 µL of 0.5 µg/mL of MTBD-tau overnight at 4 °C. Afterwards, plates were washed 3x with PBST and blocked with 5% SureBlock™ (Lubio) in PBST for 120 min. Purified autoantibodies from hospital cohort patients' plasma were diluted 1:50 in 1% SureBlock™ in PBST (sample buffer) and the anti-tau RD4 mouse monoclonal antibody to a final concentration of 0.4 µg/mL. Bovine serum albumin (BSA, Thermo Scientific), in house purified recombinant MTBD-tau, a pool of eight synthetic peptides covering the sequence of MTBD-tau with 25 amino acids length and 10 amino acids of overlap (Genscript) and an unrelated 25 amino acid length synthetic TREM2 (Triggering receptor expressed on myeloid cells 2) peptide (GenScript) were used as competing antigens. Antibody samples were incubated overnight at 4°C with serial 2-fold dilutions of antigen solutions in sample buffer, ranging from 20,000 nM to 2.44 nM. The antibody-antigen

mixtures were then added to the plates and incubated for 45 min at RT. Plates were washed three

times with PBST, followed by the addition of secondary antibodies: peroxidase AffiniPure® goat

anti-Human IgG (H+L) (109-035-088, Jackson ImmunoResearch) at 1:3,000 dilution and peroxi-

dase AffiniPure® goat anti-mouse IgG H+L (115-035-003, Jackson ImmunoResearch) at 1:2,000

dilution. Secondary antibodies were incubated for 60 min at RT and plates were then washed 4x

with PBST. TMB Chromogen Solution for ELISA (Invitrogen) was added to the plates and incu-

bated for 7 min at RT. After addition of 0.5 M $H_2SO_4$, plates were read at $OD_{450nm}$ in a plate reader

(SpectraMax® Paradigm®, Molecular Devices).

**Indirect ELISAs**

To test for polyreactivity, purified anti-tau autoantibodies were tested by indirect ELISA against

several antigens (56, 57). High-binding 384-well plates were coated overnight at 4°C with 20 µL

of 1 µg/mL of MTBD-tau, 10 µg/mL of DNA from calf-thymus (Sigma), 10 µg/mL of lipopoly-

saccharides from E.*coli* O111:B4 (Sigma), 5 µg/mL of human insulin (Sigma), 10 µg/mL of BSA,

2 µg/mL of cardiolipin solution from bovine heart (Sigma) or left uncoated. Plates were washed

3x with PBST and then blocked in 5% SureBlock™ (Lubio) in PBST for 120 min at RT. Patient

purified anti-MTBD-tau autoantibodies were diluted 1:33, IgG-depleted plasma (BioSource) 1:50

diluted and used as negative control, anti-DNP (Sigma) diluted to 6 µg/mL, anti-tau RD4 to  6

µg/mL, and pooled plasma from 20 patients diluted 1:25 in 1% SureBlock™ in PBST as positive

controls. Samples were serially diluted 12 times 1:1 with 1% SureBlock™ in PBST in the referred

plates. Samples were incubated for 120 min at RT and washed 4x with PBST. 20 µL/well of sec-

ondary antibodies diluted in 1%SureBlock™ in PBST were added as follows: peroxidase Affini-

Pure® goat anti-human IgG (H+L) (109-035-088, Jackson ImmunoResearch) diluted 1:3,000 and

added to purified MTBD-tau autoantibodies and IKC pool wells, peroxidase AffiniPure® goat

anti-mouse IgG H+L (115-035-003, Jackson ImmunoResearch) at 1:2,500 dilution and added to

anti-RD4 wells, and peroxidase AffiniPure® goat anti-rabbit IgG (H+L) (111-035-045, Jackson

ImmunoResearch) at 1:4,000 dilution and added to anti-DNP wells. Plates were then washed 3x

with PBST. 20 µL of TMB Chromogen solution for ELISA (Invitrogen) was added and incubated

for 5 min at RT. After addition of 0.5 M $H_2SO_4$, plates were read at $OD_{450nm}$ in a plate reader

(SpectraMax® Paradigm®, Molecular Devices).   For relative affinity measurements, we used an

indirect ELISA in 384-well plates (Perkin Elmer, SpectraPlate 384 HB) with MTBD-tau as a coat-

ing antigen using the following parameters: The starting concentration of all antibodies, assayed

in triplicates, was 10 µg/mL. They were successively diluted 1:3 to reach a concentration of $2\times10^{-6}$

µg/mL. As reference antibody, we used purified RD4 kindly provided by Prof. Rohan de Silva

(UCL Queen Square Institute of Neurology, London, UK). As additional controls, we used anti-

LAG3 antibody Relatlimab (23), ατ⁻ plasma sample and uncoated plates. The respective $EC_{50}$ val-

ues were then determined using logistic regression, as above, and the curves as well as the dots

were visualized.

For IgG subclassing, the following secondary antibodies were used: rabbit anti-human IgG1 (SA5-

10202, Invitrogen), rabbit anti-human IgG2 (SA5-10203, Invitrogen), rabbit anti-human IgG3

(SA5-10204, Invitrogen) or rabbit anti-human IgG4 (SA5-10205, Invitrogen) at 1:1,500 dilution,

peroxidase AffiniPure® goat anti-rabbit IgG (H+L) antibody (111-035-045, Jackson Immu-

noResearch) at 1:2,500 dilution.

For immunoglobulin light chain typing, the following secondary antibodies were used: Goat anti-

Human Kappa-HRP (19) and Goat anti-Human Lambda-HRP (19) at 1:4,000 dilution and peroxi-

dase AffiniPure® goat anti-mouse IgG H+L (115-035-003, Jackson ImmunoResearch) at 1:2,500

dilution.

For the epitope mapping experiments, a similar approach was used in which high-binding 384-

well plates were coated with 20 µL of 1 µg/mL of each MTBD-tau peptide (GenScript) in PBS

overnight at 4°C. Plasma samples and human IgG-depleted serum (MyBioSource) used as negative

control were diluted 1:50 and anti-tau RD4 mouse monoclonal antibody used as positive control

(05-804 clone 1E1/A6 Merck Millipore) was diluted to a final concentration of 6 µg/mL in 1%

SureBlock™ in PBST. The following secondary antibodies were used: peroxidase AffiniPure®

goat anti-human IgG (H+L) (109-035-088, Jackson ImmunoResearch) at 1:5,000 dilution and pe-

roxidase AffiniPure® goat anti-mouse IgG H+L (115-035-003, Jackson ImmunoResearch) at

1:2,500 dilution.

For data analysis of IgG subclassing, immunoglobulin light chain typing and epitope mapping

experiments, samples were considered reactive when the $OD_{450nm}$ was higher than the average of

all negatives $OD_{450nm}$ + 2x the standard deviation of the $OD_{450nm}$ of the negatives.

**Western blotting**

SH-SY5Y wild-type (Sigma) and cells overexpressing double-mutated tauP301L/S320F were

lysed in 0.5% Triton™ X-100 (Sigma Aldrich) in PBS, supplemented with cOmplete™ Mini

EDTA-free Protease Inhibitor Cocktail (Roche) on ice and supernatant was recovered after cen-

trifugation at 14,000g for 20 min at 4°C. Protein concentration was determined using a bicincho-

ninic acid assay (Pierce BCA Protein Assay Kit, Thermo Fisher) and sample volumes were adapted

to 30 µg of total protein. Samples were loaded onto NuPAGE 12% Bis-Tris gels (Invitrogen) and

blotted to nitrocellulose membranes (Invitrogen) using a dry iBlot 2 Gel Transfer Device (Invitro-

gen, Thermo Fisher). Membranes were cut vertically along the protein ladder and blocked with

5% SureBlock in PBST at 30 min for RT and incubated overnight at 4°C with patient purified anti-

MTBD-tau autoantibodies diluted 1:100 in 1% SureBlock, PBST. Anti-tau RD4 mouse monoclo-

nal antibody diluted 1:4,000 in was used a positive control. Monoclonal mouse anti-actin clone C4

(MAB1501R, Chemicon) diluted 1:10,000 was used as a loading control. Negative control mem-

branes were not incubated with primary antibodies. Membranes were washed 3x for 5 min with

PBST and incubated with the following secondary antibodies for 60 min at RT: peroxidase Affin-

iPure® goat anti-mouse IgG (H+L) (115-035-003, Jackson ImmunoResearch) and peroxidase Af-

finiPure® goat anti-human IgG (H+L) (109-035-088, Jackson ImmunoResearch) 1:10,000 diluted.

Membranes were washed 4x for 5 min with PBST and developed using the Immobilon Crescendo

HRP Substrate (Millipore). Imaging was performed with the Fusion SOLO S imaging system (Vil-

ber).

**Immunofluorescence**

SH-SY5Y cells were transfected with pRK5-EGFP-0N4Rtau plasmid (Addgene # 46904, a kind

gift of Dr Karen Ashe (48)) using Lipofectamine® 2000 according to manufacturer's protocol.

After 48 h cells were fixed with 4% paraformaldehyde for 20 min at RT, permeabilized with 0.5%

BSA, 0.1% Triton™X-100 in PBS for 20 min at RT and blocked with 0.5% BSA in PBS for 60min

at RT. For the immunocytochemical assays, 1:25 purified ani-MTBD-tau autoantibodies diluted

in 0.5% BSA in PBS were incubated with the cells for 60 min. Tau mouse monoclonal antibody

HT7 (MN1000 Thermo Fisher Scientific) diluted 1:500 was used as a positive control. Cells were

washed 3x with 0.5% BSA in PBS and incubated for 30 min at RT with: goat anti-mouse IgG

(H+L) cross-adsorbed Alexa Fluor ™ 555 (A-21422 Invitrogen) diluted 1:500 and counterstained

with 4,6-diamidino-2-phenylindole (DAPI) 1 mg/mL (Thermo Fisher) diluted 1:10,000 in 0.5%

BSA in PBS, and for human antibody and negative control stains with biotin AffiniPure® goat

anti-human IgG (H+L) (109-065-003, Jackson ImmunoResearch) diluted 1:200 in 0.5% BSA in

PBS. Samples were 3x washed with 0.5% BSA in PBS. For human antibody stains, samples were

further incubated for 30 min at RT with streptavidin Alexa Fluor™ 594 conjugate diluted 1:200

and counterstained with DAPI diluted 1:10,000 in 0.5% BSA in PBS. Cells were mounted on glass

slides with Fluorescence Mounting Medium (Thermo Fisher Scientific) and imaged using a Leica

TCS SP5 confocal laser scanning microscope. Imaging was performed with equipment maintained

by the Center for Microscopy and Image Analysis, University of Zurich.

***In vitro* MTBD-tau aggregation assay**

MTBD-tau *in vitro* aggregation experiments were performed as previously described (31). Briefly,

7 µM of in-house purified recombinant MTBD-tau, 3.5 µM of heparin (Santa Cruz Biotechnology)

and 10 µM of thioflavin T (ThT, Sigma) were diluted in PBS. The patient purified anti-tau auto-

antibodies and controls (plasma sample reactive against the LAG3 and IgG-purified using Protein

G Sepharose (Cytiva)) were added at the indicated apparent stoichiometries in Figure 3. The mix-

tures with a total volume of 200 µl were added to black 96-well polystyrene microplates (Nunc,

Prod. No. 265301) and ThT fluorescence (450/480 nm ex/em filters; bottom read mode) was meas-

ured at 37°C under continuous orbital shaking (425 cpm) every 15 min for 96 h using a FLUOstar

Omega microplate reader (BMG Labtech). The mean baseline fluorescence values were sub-

tracted from the mean fluorescence values at each time point which were then normalized to max-

imum baseline-subtracted fluorescence values and multiplied by 100 (58).

**Statistical analysis**

Antibody titers were defined as the negative logarithm half-maximal responses ($-\log_{10}(EC_{50})$) ob-

tained by fitting the $OD_{450nm}$ of the eight dilution points of each sample tested in the microELISA

to a logistic regression fitter. We classified as positives samples with a cut-off of $-\log_{10}(EC_{50}) \geq 1.8$

(25), corresponding to a nominal dilution of $> 1/64$. Non-informative samples (fitting error $>20\%$

$-\log_{10}(EC_{50})$ or high background) were excluded from the analysis (25). In cases where more than

one sample was available for the same individual the most recent $\log_{10}(EC_{50})$ value was used.

Age is presented as median with interquartile range (IQR) and comparisons were performed using

non-parametric Mann-Whitney U test. Categorized age groups and sex of positives and negatives

are shown as percentages and compared using two-proportions Z-test or $\chi^2$ test for trend in propor-

tions. Log-binomial regression models (28, 59) using MTBD-tau autoreactivity were employed to

estimate age-and-sex adjusted RRs (aRR) and 95% confidence intervals (CIs), and to investigate

the association between the detection of anti-MTBD-tau IgG autoantibodies and different demo-

graphic features.

For the AD cohort microELISA screen, $\log_{10}(EC_{50})$ values were compared using Mann-Whitney

U test. Additionally, Bayesian logistic regression was conducted (25, 60-62), using $-\text{logit}_{10}(EC_{50})$

values as outcome, i.e. without dichotomising the outcome using the R package rstanarm and the

following priors (prior=normal[0, 2.5, autoscale=TRUE],prior_intercept = normal[5000, 2.5, au-

toscale=TRUE)] prior_aux = exponential [1, autoscale =TRUE]. We aimed to confirm the positive

association between ICD-10 codes previously identified using a conventional logistic regression

model with high $-\log_{10}(EC_{50})$ values. Each ICD-10 code was analyzed in an independent logistic

regression and adjusted for age and sex.

The association between MTBD-tau-autoreactivity and neurological and systemic disorders, re-

spectively, was analysed by applying multivariate log-binomial regression models to estimate

aRRs and 95% CIs. For neurological disorders, 23 major groups of ICD-10 codes (Supplemental

Table 3) corresponding to neurological disorders identified at least once in the positive samples

were used. For systemic disorders, the 27 major groups of ICD-10 codes (Supplemental Table 4)

or 276 individual ICD-10 codes corresponding to systemic disorders identified at least once in the

positive samples and with at least 200 total counts were used to avoid overinterpretation of rare

cases of disease. Individual disease entities with a P value < 0.05 Bonferroni corrected for multiple

comparisons were included in a multivariate log-binomial regression analysis.

For the association between MTBD-tau-autoreactivity and clinical laboratory parameters, we used

laboratory parameters with more than 2,000 total counts and calculated median values of the total

values available for each patient in case of repetition of the clinical laboratory test. We used mul-

tivariate log-binomial regression models to estimate aRR and 95% CI using 106 clinical laboratory

tests.

Statistical significance was defined by 2-tailed P-value ≤ 0.05. Statistical analyses and data visu-

alization were performed using R version 4.3.2 and RStudio version 1.4.1106 (63).

**Study approval**

Collection of samples and clinical data were conducted according to study protocols approved by

the Cantonal Ethics Committee of the Canton of Zurich, Switzerland (KEK-ZH Nr. 2015-0561,

BASEC-Nr. 2018-01042, and BASEC-Nr. 2020-01731).

**Data availability:**

Data and material requests should be addressed to the corresponding authors. Materials will be

shared upon approval by an ethics committee or review board and a material transfer agreement.

**List of Supplementary Materials:**

Supplemental Figure 1, 2, 3 and 4

Supplemental Table 1, 2, 3 and 4

**References**

1. Gu Y, Oyama F, and Ihara Y. Tau is widely expressed in rat tissues. *J Neurochem.* 1996;67(3):1235-44.
2. Uhlen M, Fagerberg L, Hallstrom BM, Lindskog C, Oksvold P, Mardinoglu A, et al. Proteomics. Tissue-based map of the human proteome. *Science.* 2015;347(6220):1260419.
3. Sotiropoulos I, Galas MC, Silva JM, Skoulakis E, Wegmann S, Maina MB, et al. Atypical, non-standard functions of the microtubule associated Tau protein. *Acta Neuropathol Commun.* 2017;5(1):91.
4. Rinschen MM, Gödel M, Grahammer F, Zschiedrich S, Helmstädter M, Kretz O, et al. A Multi-layered Quantitative In Vivo Expression Atlas of the Podocyte Unravels Kidney Disease Candidate Genes. *Cell Rep.* 2018;23(8):2495-508.
5. Ho KH, Yang X, Osipovich AB, Cabrera O, Hayashi ML, Magnuson MA, et al. Glucose Regulates Microtubule Disassembly and the Dose of Insulin Secretion via Tau Phosphorylation. *Diabetes.* 2020;69(9):1936-47.
6. Kosik KS, Joachim CL, and Selkoe DJ. Microtubule-associated protein tau (tau) is a major antigenic component of paired helical filaments in Alzheimer disease. *Proc Natl Acad Sci U S A.* 1986;83(11):4044-8.
7. Joachim CL, Morris JH, Kosik KS, and Selkoe DJ. Tau antisera recognize neurofibrillary tangles in a range of neurodegenerative disorders. *Ann Neurol.* 1987;22(4):514-20.
8. Hanseeuw BJ, Betensky RA, Jacobs HIL, Schultz AP, Sepulcre J, Becker JA, et al. Association of Amyloid and Tau With Cognition in Preclinical Alzheimer Disease: A Longitudinal Study. *JAMA Neurol.* 2019;76(8):915-24.
9. Mattsson N, Zetterberg H, Janelidze S, Insel PS, Andreasson U, Stomrud E, et al. Plasma tau in Alzheimer disease. *Neurology.* 2016;87(17):1827-35.
10. Janelidze S, Mattsson N, Palmqvist S, Smith R, Beach TG, Serrano GE, et al. Plasma P-tau181 in Alzheimer's disease: relationship to other biomarkers, differential diagnosis, neuropathology and longitudinal progression to Alzheimer's dementia. *Nat Med.* 2020;26(3):379-86.
11. Mielke MM, Hagen CE, Wennberg AMV, Airey DC, Savica R, Knopman DS, et al. Association of Plasma Total Tau Level With Cognitive Decline and Risk of Mild Cognitive Impairment or Dementia in the Mayo Clinic Study on Aging. *JAMA Neurol.* 2017;74(9):1073-80.
12. Palmqvist S, Tideman P, Mattsson-Carlgren N, Schindler SE, Smith R, Ossenkoppele R, et al. Blood Biomarkers to Detect Alzheimer Disease in Primary Care and Secondary Care. *JAMA.* 2024.
13. Asuni AA, Boutajangout A, Quartermain D, and Sigurdsson EM. Immunotherapy targeting pathological tau conformers in a tangle mouse model reduces brain pathology with associated functional improvements. *J Neurosci.* 2007;27(34):9115-29.
14. Boutajangout A, Ingadottir J, Davies P, and Sigurdsson EM. Passive immunization targeting pathological phospho-tau protein in a mouse model reduces functional decline and clears tau aggregates from the brain. *J Neurochem.* 2011;118(4):658-67.
15. Congdon EE, and Sigurdsson EM. Tau-targeting therapies for Alzheimer disease. *Nat Rev Neurol.* 2018;14(7):399-415.

16. Rothstein TL. Natural Antibodies as Rheostats for Susceptibility to Chronic Diseases in the
Aged. *Front Immunol.* 2016;7:127.

17. Lutz HU, Binder CJ, and Kaveri S. Naturally occurring auto-antibodies in homeostasis and
disease. *Trends Immunol.* 2009;30(1):43-51.

18. Bastard P, Gervais A, Le Voyer T, Rosain J, Philippot Q, Manry J, et al. Autoantibodies
neutralizing type I IFNs are present in ~4% of uninfected individuals over 70 years old and
account for ~20% of COVID-19 deaths. *Sci Immunol.* 2021;6(62).

19. Jaycox JR, Dai Y, and Ring AM. Decoding the autoantibody reactome. *Science.*
2024;383(6684):705-7.

20. Florance NR, Davis RL, Lam C, Szperka C, Zhou L, Ahmad S, et al. Anti-N-methyl-D-
aspartate receptor (NMDAR) encephalitis in children and adolescents. *Ann Neurol.*
2009;66(1):11-8.

21. Lennon VA, Wingerchuk DM, Kryzer TJ, Pittock SJ, Lucchinetti CF, Fujihara K, et al. A serum
autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis. *Lancet.*
2004;364(9451):2106-12.

22. Ferrero J, Williams L, Stella H, Leitermann K, Mikulskis A, O'Gorman J, and Sevigny J. First-
in-human, double-blind, placebo-controlled, single-dose escalation study of aducanumab
(BIIB037) in mild-to-moderate Alzheimer's disease. *Alzheimers Dement (N Y).*
2016;2(3):169-76.

23. Bartos A, Fialová L, and Švarcová J. Lower Serum Antibodies Against Tau Protein and
Heavy Neurofilament in Alzheimer's Disease. *J Alzheimers Dis.* 2018;64(3):751-60.

24. Kronimus Y, Albus A, Balzer-Geldsetzer M, Straub S, Semler E, Otto M, et al. Naturally
Occurring Autoantibodies against Tau Protein Are Reduced in Parkinson's Disease
Dementia. *PLoS One.* 2016;11(11):e0164953.

25. Emmenegger M, De Cecco E, Lamparter D, Jacquat RPB, Riou J, Menges D, et al.
Continuous population-level monitoring of SARS-CoV-2 seroprevalence in a large
European metropolitan region. *iScience.* 2023;26(2):105928.

26. Emmenegger M, Zografou C, Yile D, Hoyt LR, Gudneppanavar R, Chincisan A, et al. The
Cystic Fibrosis Transmembrane Regulator Controls Tolerogenic Responses to Food
Allergens in Mice and Humans. *medRxiv.* 2024.

27. Senatore A, Frontzek K, Emmenegger M, Chincisan A, Losa M, Reimann R, et al. Protective
anti-prion antibodies in human immunoglobulin repertoires. *EMBO Mol Med.*
2020;12(9):e12739.

28. Diaz-Quijano FA. A simple method for estimating relative risk using logistic regression.
*BMC Med Res Methodol.* 2012;12:14.

29. Donoghoe MW, and Marschner IC. Logbin: An R Package for Relative Risk Regression
Using the Log-Binomial Model. *Journal of Statistical Software* 2018;86(21).

30. de Silva R, Lashley T, Gibb G, Hanger D, Hope A, Reid A, et al. Pathological inclusion bodies
in tauopathies contain distinct complements of tau with three or four microtubule-
binding repeat domains as demonstrated by new specific monoclonal antibodies.
*Neuropathol Appl Neurobiol.* 2003;29(3):288-302.

31. Apetri A, Crespo R, Juraszek J, Pascual G, Janson R, Zhu X, et al. A common antigenic motif
recognized by naturally occurring human V. *Acta Neuropathol Commun.* 2018;6(1):43.

32.  Pase MP, Beiser AS, Himali JJ, Satizabal CL, Aparicio HJ, DeCarli C, et al. Assessment of
Plasma Total Tau Level as a Predictive Biomarker for Dementia and Related
Endophenotypes. *JAMA Neurol.* 2019;76(5):598-606.

33.  Barini E, Plotzky G, Mordashova Y, Hoppe J, Rodriguez-Correa E, Julier S, et al. Tau in the
brain interstitial fluid is fragmented and seeding-competent. *Neurobiol Aging.*
2022;109:64-77.

34.  Dahm L, Ott C, Steiner J, Stepniak B, Teegen B, Saschenbrecker S, et al. Seroprevalence of
autoantibodies against brain antigens in health and disease. *Ann Neurol.* 2014;76(1):82-
94.

35.  Yu G, Chen J, Xu Y, Zhu C, Yu H, Liu S, et al. Generation of goats lacking prion protein. *Mol*
*Reprod Dev.* 2009;76(1):3.

36.  Tsuboi Y, Uitti RJ, Delisle MB, Ferreira JJ, Brefel-Courbon C, Rascol O, et al. Clinical features
and disease haplotypes of individuals with the N279K tau gene mutation: a comparison
of the pallidopontonigral degeneration kindred and a French family. *Arch Neurol.*
2002;59(6):943-50.

37.  Vallés-Saiz L, Peinado-Cahuchola R, Ávila J, and Hernández F. Microtubule-associated
protein tau in murine kidney: role in podocyte architecture. *Cell Mol Life Sci.*
2022;79(2):97.

38.  Congdon EE, Ji C, Tetlow AM, Jiang Y, and Sigurdsson EM. Tau-targeting therapies for
Alzheimer disease: current status and future directions. *Nat Rev Neurol.* 2023;19(12):715-
36.

39.  ClinicalTrial.gov N, Dominantly Inherited Alzheimer Network Trial: An Opportunity to
Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals With
a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation (DIAN-TU).
https://clinicaltrials.gov/study/NCT05269394?cond=Alzheimer%20Disease&term=E2814
&rank=1; 2023.

40.  Barton ME, Van Den Steen B, Van Tricht HLG, Byrnes W, Purcell FE, Southcott SA, et al.
Update on the TOGETHER study: a patient- and investigator-blind, randomized, placebo-
controlled study evaluating the efficacy, safety and tolerability of bepranemab, UCB0107,
in prodromal-to-mild Alzheimer's disease. *Alzheimer's & Dementia.*
2022;18(S10):e068973.

41.  Moscoso A, Grothe MJ, Ashton NJ, Karikari TK, Lantero Rodríguez J, Snellman A, et al.
Longitudinal Associations of Blood Phosphorylated Tau181 and Neurofilament Light Chain
With Neurodegeneration in Alzheimer Disease. *JAMA Neurol.* 2021;78(4):396-406.

42.  Barthélemy NR, Li Y, Joseph-Mathurin N, Gordon BA, Hassenstab J, Benzinger TLS, et al. A
soluble phosphorylated tau signature links tau, amyloid and the evolution of stages of
dominantly inherited Alzheimer's disease. *Nat Med.* 2020;26(3):398-407.

43.  Karikari TK, Pascoal TA, Ashton NJ, Janelidze S, Benedet AL, Rodriguez JL, et al. Blood
phosphorylated tau 181 as a biomarker for Alzheimer's disease: a diagnostic performance
and prediction modelling study using data from four prospective cohorts. *Lancet Neurol.*
2020;19(5):422-33.

44.  Park JC, Han SH, Yi D, Byun MS, Lee JH, Jang S, et al. Plasma tau/amyloid-β1-42 ratio
predicts brain tau deposition and neurodegeneration in Alzheimer's disease. *Brain.*
2019;142(3):771-86.

45.  Palmqvist S, Janelidze S, Quiroz YT, Zetterberg H, Lopera F, Stomrud E, et al. Discriminative
Accuracy of Plasma Phospho-tau217 for Alzheimer Disease vs Other Neurodegenerative
Disorders. *JAMA.* 2020;324(8):772-81.
46.  Yanamandra K, Patel TK, Jiang H, Schindler S, Ulrich JD, Boxer AL, et al. Anti-tau antibody
administration increases plasma tau in transgenic mice and patients with tauopathy. *Sci
Transl Med.* 2017;9(386).
47.  Mielke MM, Dage JL, Frank RD, Algeciras-Schimnich A, Knopman DS, Lowe VJ, et al.
Performance of plasma phosphorylated tau 181 and 217 in the community. *Nat Med.*
2022;28(7):1398-405.
48.  https://www.proteinatlas.org/ENSG00000105835-NAMPT/tissue.
49.  St Germaine-Smith C, Metcalfe A, Pringsheim T, Roberts JI, Beck CA, Hemmelgarn BR, et
al. Recommendations for optimal ICD codes to study neurologic conditions: a systematic
review. *Neurology.* 2012;79(10):1049-55.
50.  Fischer I. Big Tau: What We Know, and We Need to Know. *eNeuro.* 2023;10(5).
51.  Meng J, and Lei P. Plasma pTau181 as a biomarker for Alzheimer's disease. *MedComm
(2020).* 2020;1(1):74-6.
52.  Telser J, Risch L, Saely CH, Grossmann K, and Werner P. P-tau217 in Alzheimer's disease.
*Clin Chim Acta.* 2022;531:100-11.
53.  Gonzalez-Ortiz F, Turton M, Kac PR, Smirnov D, Premi E, Ghidoni R, et al. Brain-derived
tau: a novel blood-based biomarker for Alzheimer's disease-type neurodegeneration.
*Brain.* 2023;146(3):1152-65.
54.  Organization WH. 2004.
55.  Hedgepeth CM, Conrad LJ, Zhang J, Huang HC, Lee VM, and Klein PS. Activation of the Wnt
signaling pathway: a molecular mechanism for lithium action. *Dev Biol.* 1997;185(1):82-
91.
56.  Bunker JJ, Erickson SA, Flynn TM, Henry C, Koval JC, Meisel M, et al. Natural polyreactive
IgA antibodies coat the intestinal microbiota. *Science.* 2017;358(6361).
57.  Mouquet H, Scheid JF, Zoller MJ, Krogsgaard M, Ott RG, Shukair S, et al. Polyreactivity
increases the apparent affinity of anti-HIV antibodies by heteroligation. *Nature.*
2010;467(7315):591-5.
58.  Orrú CD, Yuan J, Appleby BS, Li B, Li Y, Winner D, et al. Prion seeding activity and infectivity
in skin samples from patients with sporadic Creutzfeldt-Jakob disease. *Sci Transl Med.*
2017;9(417).
59.  McNutt LA, Wu C, Xue X, and Hafner JP. Estimating the relative risk in cohort studies and
clinical trials of common outcomes. *Am J Epidemiol.* 2003;157(10):940-3.
60.  Emmenegger M, Emmenegger V, Shambat SM, Scheier TC, Gomez-Mejia A, Chang CC, et
al. Antiphospholipid antibodies are enriched post-acute COVID-19 but do not modulate
the thrombotic risk. *Clin Immunol.* 2023;257:109845.
61.  M. Emmenegger VE, in Zenodo, 2023. https://doi.org/10.5281/zenodo.10051979. .
62.  Losa M, Emmenegger M, De Rossi P, Schurch PM, Serdiuk T, Pengo N, et al. The ASC
inflammasome adapter governs SAA-derived protein aggregation in inflammatory
amyloidosis. *EMBO Mol Med.* 2024;16(9):2024-42.
63.  RStudioTeam. (RStudio P, Boston, MA, 2021).

**Acknowledgments:**

The authors wish to thank the hospital patients and blood donors for their generous altruistic contributions to this study. Imaging was performed with equipment maintained by the Center for Microscopy and Image Analysis, University of Zurich, Switzerland, and electrospray ionization-mass spectrometry at the Functional Genomics Center Zurich, University of Zurich, Switzerland. We thank Prof. Rohan de Silva (UCL Queen Square Institute of Neurology, London, UK) for providing the purified anti-MTBD-tau antibody RD4. We thank Dr. Marco Losa for the generous provision of secondary antibodies for light chain typing and Magdalena Bialkowska, Lisa Caflisch, Berre Doğançay, Julie Domange, Marigona Imeri, Lorène Mottier, Rea Müller, Antonella Rosati, Dezirae Schneider, and Anne Wiedmer for help with the high-throughput assays. Insightful advice about programming in R software was provided by Reto Guadagnini.

**Funding:**

University of Zürich, Candoc grant FK-19-025 (ADM)

Swiss Personalised Health Network, SPHN, driver project grant 2017DRI17 (AA)

Swiss National Foundation SNF (SNSF grant ID 179040 and grant ID 207872, Sinergia grant ID 183563) (AA)

European Research Council ERC Prion2020, 670958 (AA)

Nomis Foundation (AA)

Innovation Fund of the University Hospital Zurich (INOV00096) (AA)

University Hospital Zurich Foundation grant USZF27101 (with contributions of the NOMIS Foundation, the Schwyzer Winiker Stiftung, and the Baugarten Stiftung, AA, ME)

HMZ ImmunoTarget grant, Stiftung Neuropath and GELU Foundation (AA)

Michael J. Fox Foundation (grant ID MJFF-020710 and MJFF-021073) (SH).

**Author contributions:**

Conceived and designed the experiments: ADM, SH, AA. Supervised the study: SH, AA. Per-

formed tau protein purification: ADM, EDC, JG. Performed tau microELISA automated screen:

ADM, ME. Performed amyloid-ß pyroglutamate and cellular prion protein microELISA auto-

mated screen: MC, KF, ME. Maintained microELISA automated platform: ME. Performed puri-

fication, validation and characterization of anti-tau autoantibodies: ADM, JG. Maintained the clin-

ical database: ME, AC. Performed data analysis and visualization: ADM. Wrote the first draft of

manuscript: ADM. Corrected and advised on subsequent versions of the manuscript: ADM, ME,

SH, AA. All authors reviewed and approved the final version of the manuscript and consented to

be accountable for the work.

**Figures**

**Figure 1. Study overview and seroprevalence of anti-MTBD-tau IgG autoantibodies. A.**

Flowchart of the study design. **B.-C.** Distribution of -$\log_{10}(EC_{50})$ values obtained from the micro-

ELISA screen of hospital (B) and blood donor (C) plasma samples. **D.** Age- and sex-adjusted risk

ratio ratios and 95% confidence intervals (CI; I bars) for the detection of anti-tau autoantibodies

in hospital and blood-bank plasma samples. **E.** Replicability of microELISA duplicates with inde-

pendent estimation of the -$\log_{10}(EC_{50})$ values. Dashed lines: cut-off value of -$\log_{10}(EC_{50})$ = 1.8. **F.**

-$\log_{10}(EC_{50})$ values of samples tested by microELISA against MTBD-tau and amyloid-ß pyroglu-

tamate. **G.** Same as shown in (F), but for samples tested against MTBD-tau and the cellular prion

protein (PrP$^{C}$).

**Figure 2. Biophysical characterization of samples from $\alpha\tau^+$ patients. A**. Indirect ELISA of purified anti-MTBD-tau autoantibodies from four $\alpha\tau^+$ samples and from 6 pooled $\alpha\tau^+$ samples. All antibodies were assayed at the same concentration to compare their $EC_{50}$ to that of RD4. Relatimab (anti-LAG3) was used as negative control. $EC_{50}$ values are indicated in the Figure. n.d.: not determined. **B.** Principle of competition ELISA. **C.** Competition ELISA of purified anti-tau autoantibodies from four $\alpha\tau^+$ patients against albumin, recombinant MTBD-tau, a pool of synthetic peptides spanning the sequence of MTBD-tau and synthetic TREM2. RD4 antibody: positive control. Mean values ± SD of two replicates. **D.** Indirect ELISA to assess the reactivity of purified anti-tau autoantibodies against albumin, cardiolipin, double-stranded DNA, insulin, lipopolysaccharides

(LPS), MTBD-tau and uncoated plates. Positive controls were as follows: RD4 antibody for

MTBD-tau, anti-DNP antibody for cardiolipin, albumin and DNA and the IKC pool of 20 heparin

plasma samples for insulin, LPS and uncoated plates. Mean values ± SD of two replicates are

shown. **E.** Representative immunofluorescence images of SH-SY5Y cells expressing EGFP-

0N4R-tau using affinity-purified anti-tau autoantibodies. HT7 pan-tau antibody: positive control.

No primary antibody: negative control. Scale bar: 60 µm. **F.** Western blot of cell lysates from wild-

type (SH-SY5Y WT) or $tau^{P301L/S320F}$-overexpressing cells (SH-SY5Y tau) using purified anti-tau

autoantibodies from four $\alpha\tau^+$ patients. Positive control: RD4. Negative control: omission of pri-

mary antibody. **G.** IgG subclass typing of 13 $\alpha\tau^+$ plasma samples. Gray and white boxes: reactive

and non-reactive samples, respectively. **H.** κ/λ light chain typing of the samples in F. **I.** Epitope

mapping of the samples in Figure 2F against 25mer MTBD-tau peptides with 10 residues overlap.

Vertical axis: sequences of the MTBD-tau peptides covering the sequence of MTBD-tau.

**Figure 3.** Natural ατ autoantibodies inhibit tau aggregation and impair tau detection. A. Kinetic

aggregation curves of MTBD-tau followed by ThT fluorescence in the absence (n=12) or presence

of purified ατ autoantibodies (patient P7 (n=4) and P8 (n=2)) or antibodies from an ατ- sample

(n=6). Stoichiometric ratios as indicated. Gray lines indicate individual replicates and black lines

the average of the replicates. B. Principle of the competition sandwich ELISA. C. Competitive

sandwich ELISA to assess the ability of purified anti-tau autoantibodies with matching (P4-P6)

and non-matching (P2 and P3) epitopes to the commercial detection antibody, ab64193, to impair

858    the detection of free tau441 spiked in plasma (dark blue). Serial dilutions of purified anti-tau anti-

859    bodies are shown in (C) and binding at highest anti-tau antibody concentrations in (D).

**Figure 4. Demographic characteristics of hospital patients' cohort. A.** Age and sex pyramid of positive and negative individuals. **B.** Percentage of positives among hospital patients across decadic age groups. The numbers on top of each bar correspond to the positivity rates. $\chi^2$ test for trend in proportions. **C.** RR ± 95% CI for $\alpha\tau^+$ autoantibodies according to sex and age groups. Asterisks: P < 0.05 after Bonferroni correction. **D.** Break-down of samples by clinical department. Asterisks: P < 0.05 (two-proportions z-test with Bonferroni correction). **E.** aRR ± 95% CI for $\alpha\tau^+$ samples by clinical department. Asterisks: P < 0.05 after Bonferroni correction.

**Figure 5. aRR of MTBD-tau-autoreactivity for major groups of neurological disorders and reactivity profiles for AD screen**. **A.** aRR and 95% CI (I bars) for $\alpha\tau^+$ autoantibodies according to different groups of neurological disorders. No P values remained significant after Bonferroni correction. **B.** Boxplots showing the 25th, 50th (median) and 75th percentiles of the reactivity profiles for AD and control patients (Mann-Whitney U test).

**Figure 6. Association of MTBD-tau IgG autoantibodies with systemic disorders and clinical laboratory data. A.** aRR ± 95% CI (bars) for ατ⁺ autoantibodies grouped 27 different main systemic clinical conditions. Asterisks: P < 0.05 after Bonferroni correction. **B.** -log$_{10}$(P value) of the log-binomial regression for the presence of plasma MTBD-tau IgG autoantibodies for 276 disorders according to ICD-10 codes and adjusted for age and sex. Triangles pointing upwards and downwards: positive and coefficients, respectively; gray dashed line: P < 0.05 after Bonferroni correction (here and henceforth). P values significant after Bonferroni adjustment are labelled with the ICD codes. **C.** Same as (A), but according to individual disease entities from (B). **D**. Bayesian

logistic regression adjusted for age and sex on ICD-10 codes significantly associated in B. and

using -$logit_{10}(EC_{50})$ as continuous outcome (odds ratio $\pm$ 95% credible intervals). This analysis

confirms the positive association of these ICD-10 codes with $\alpha\tau$ reactivity (from B). **E.** $log_{10}$(P

value) of the log-binomial regression for the presence of plasma MTBD-tau IgG autoantibodies

and clinical laboratory parameters. P values significant after Bonferroni adjustment are labelled

with the ICD codes. The gray dashed line indicates the significance level after Bonferroni correc-

tion (<0.05/106=0.00047). eGFR CKD-EPI 2009: estimated glomerular filtration rate using the

Chronic Kidney Disease Epidemiology Collaboration 2009 equation; eGFR BIS1: estimated glo-

merular filtration rate using the older adults Berlin Initiative Study 1 equation. INR: international

normalized ratio. LDL: low-density lipoprotein. HDL: high-density lipoprotein. **F.** Calculated

prevalence of different ICD-10 codes in the total cohort (dark blue), $\alpha\tau^{-}$ (intermediate blue) and

$\alpha\tau^{+}$ samples (light blue). P-values < 0.001 (two-proportions z-test).